Importance With the advent of potent BCR:: ABL1 tyrosine kinase inhibitors (TKIs),
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is now …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

The impact of achieving complete molecular response (CMR) in Philadelphia chromosome-
positive (Ph+) acute lymphoblastic leukemia (ALL) remains undefined. We evaluated the …

Abstract Historically, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
(ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell …

Introduction: Acute lymphoblastic leukemia (ALL) is the first neoplasm where the
assessment of early response to therapy by minimal residual disease (MRD) monitoring has …

BACKGROUND The clinical efficacy of hyperfractionated cyclophosphamide, vincristine,
doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that …

Promising results have been shown with the combination of ponatinib and chemotherapy in
adults with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) …

Tyrosine kinase inhibitors have improved survival for patients with Philadelphia
chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis for …

This multicenter trial was conducted to determine whether the addition of dasatinib to
chemotherapy followed by an allogeneic hematopoietic cell transplant (HCT) in patients with …